What is William Blair's Estimate for AXSM FY2026 Earnings?

Key Points

• William Blair raised their FY2026 EPS estimate for Axsome Therapeutics to $1.46 per share, up from the previous estimate of $1.33, despite the current consensus being a loss of $2.79 per share.
• A majority of analysts rate Axsome Therapeutics stock positively, with two issuing a "Strong Buy," fourteen a "Buy," and one a "Sell." The current consensus price target is $177.93.
• Recent insider trading included notable share sales, with COO Mark L. Jacobson and Director Roger Jeffs selling significant shares, indicating a decrease in insider ownership of the company.

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - William Blair upped their FY2026 EPS estimates for Axsome Therapeutics in a report released on Friday, October 10th. William Blair analyst M. Minter now forecasts that the company will earn $1.46 per share for the year, up from their prior forecast of $1.33. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.

A number of other analysts have also recently issued reports on AXSM. Wells Fargo & Company raised shares of Axsome Therapeutics to a "strong-buy" rating in a research note on Wednesday, September 3rd. Needham & Company LLC reissued a "buy" rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a research note on Monday, August 4th. Royal Bank Of Canada raised their target price on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the company an "outperform" rating in a research note on Tuesday, August 5th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Axsome Therapeutics in a research note on Wednesday, October 8th. Finally, Bank of America raised their target price on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Axsome Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $177.93.

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $121.71 on Monday. The firm has a fifty day moving average price of $116.84 and a 200-day moving average price of $109.84. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.51. The stock has a market cap of $6.07 billion, a PE ratio of -24.01 and a beta of 0.52. Axsome Therapeutics has a 1 year low of $75.56 and a 1 year high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.00) by $0.08. The firm had revenue of $150.04 million during the quarter, compared to analysts' expectations of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 45,783 shares of Axsome Therapeutics stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $114.48, for a total value of $5,241,237.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Roger Jeffs sold 20,000 shares of Axsome Therapeutics stock in a transaction on Thursday, August 28th. The stock was sold at an average price of $121.60, for a total transaction of $2,432,000.00. Following the completion of the transaction, the director directly owned 90,974 shares of the company's stock, valued at $11,062,438.40. The trade was a 18.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 243,332 shares of company stock valued at $28,824,746 in the last three months. Corporate insiders own 22.40% of the company's stock.

Hedge Funds Weigh In On Axsome Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd purchased a new position in shares of Axsome Therapeutics in the 1st quarter worth $25,000. Quantbot Technologies LP bought a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $31,000. AlphaQuest LLC bought a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $38,000. Neo Ivy Capital Management bought a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $41,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Axsome Therapeutics in the 1st quarter worth about $47,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.